Physical Distancing to Avoid COVID-19 and the Association With Humanistic Burden in Immunocompromised Adults – The Eagle Study

Speaker(s)

Powell PA1, Williams P2, Herring TA3, Venkatesan S4, Arnetorp S5, Lloyd A6, Marcus J7, Ouwens M8, Rohay J9, Severens JL10, Yokota RTC11, Maia T12, Taylor S4, Krol M13, Ware Jr. JE14
1University of Sheffield, Sheffield, UK, 2IQVIA, Courbevoie, Île-de-France, France, 3AstraZeneca, Wilmington, DE, USA, 4AstraZeneca, Cambridge, Cambridgeshire, UK, 5AstraZeneca, Gothenberg, Västergötland, Sweden, 6Acaster Lloyd Consulting Ltd, Oxford, Oxfordshire, UK, 7IQVIA, US, Washington, DC, USA, 8AstraZeneca, Mölndal, Västra Götaland, Sweden, 9IQVIA, Pittsburgh, PA, USA, 10Severens HTA Consultancy, Venray, Limburg, Netherlands, 11P95, Leuven, Flemish Brabant, Belgium, 12IQVIA, Porto Salvo, Oeiras, Portugal, 13IQVIA, Amsterdam, ZH, Netherlands, 14John Ware Research Group, Worcester, MA, USA

OBJECTIVES: Immunocompromised (IC) adults may continue to physically distance to avoid COVID-19, which can impact their lives. This study analysis aimed to quantify current physical distancing behaviors of IC adults and the association of those behaviors with health-related quality of life (HRQoL) outcomes.

METHODS: A cross-sectional online survey, the EAGLE Study, was conducted December 2022 - June 2023 in IC adults, non-IC adults, and children-caregiver dyads, in the US and UK. Adults completed the Physical Distancing Scale-COVID-19 (PDS-C19), a novel 7-item instrument to assess past 4-week physical distancing behaviors (higher score = more distancing) and psychometrically validated on a subset of EAGLE participants, and these HRQoL instruments: SF-12v2 (includes SF-6D), QDIS-7, EQ-5D-5L, HADS (anxiety and depression), DMOL (loneliness), and WPAI+CIQ:SHP (productivity loss). Data from adult IC participants with completed surveys (excluding the psychometric validation adults’ subset) were analyzed. Pearson correlation coefficients were used to assess associations between physical distancing and outcomes. Adjusted analyses via structural equation modelling are ongoing.

RESULTS: Among 2,024 IC adults, 79.8% were female, the most common age band was 45-54 years (25.3%), 77.0% were from the US, and 65.3% had received 3+ COVID-19 vaccine doses. The most common IC categories were ‘other IC conditions’ (29.8%), conditions requiring ‘immunosuppressant treatment’ (22.3%) and ‘active solid tumor’ (18.5%). The mean PDS-C19 score was 46.4 (i.e., the average response was ‘sometimes’ for avoidance items). Mean or proportional outcomes were SF-12v2 (Mental Component Score [MCS]=45.41; Physical Component Score [PCS]=40.86); QDIS-7=54.55; HADS (anxiety=8.74; depression=6.40); DMOL (15.4% felt lonely ‘often/always’); WPAI (absenteeism=7.18%; presenteeism 17.32%); EQ-5D utility=0.68; SF-6D=0.65. PDS-C19 score correlations with outcomes were: SF-12v2 (MCS=-0.27, PCS=PCS-0.32); QDIS-7=0.78; DMOL=0.31; HADS (anxiety=0.34, depression=0.39); WPAI (absenteeism=0.33, presenteeism=0.51); EQ-5D utility=-0.33; SF-6D=-0.37.

CONCLUSIONS: Three years after COVID-19 emergence, we observed distancing behaviors to avoid COVID-19 in IC individuals and correlations of higher distancing behaviors with higher impairment across diverse HRQoL outcomes.

Code

PCR172

Topic

Patient-Centered Research

Topic Subcategory

Patient Behavior and Incentives, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Infectious Disease (non-vaccine), No Additional Disease & Conditions/Specialized Treatment Areas